Guardant Health, Inc. raised financial guidance for the full year of 2024. For the period, the company expects revenue excluding screening to be in the range of $675 to $685 million, representing growth of 20% to 21% compared to full year 2023 This compares to the prior range of $655 to $670 million, representing growth of 16% to 19%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
27.93 USD | +1.90% | +6.77% | +3.25% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.25% | 3.43B | |
-41.39% | 8.02B | |
-0.37% | 2.27B | |
-19.19% | 2.03B | |
-22.57% | 1.63B | |
+32.82% | 1.16B | |
-8.30% | 703M | |
+14.12% | 714M | |
-31.22% | 500M | |
-4.97% | 279M |
- Stock Market
- Equities
- GH Stock
- News Guardant Health, Inc.
- Guardant Health, Inc. Raises Financial Guidance for the Full Year of 2024